Literature DB >> 10525957

Estimation of the target stem-cell population size in chronic myeloid leukemogenesis.

T Radivoyevitch1, M J Ramsey, J D Tucker.   

Abstract

Estimation of the number of hematopoietic stem cells capable of causing chronic myeloid leukemia (CML) is relevant to the development of biologically based risk models of radiation-induced CML. Through a comparison of the age structure of CML incidence data from the Surveillance, Epidemiology, and End Results (SEER) Program and the age structure of chromosomal translocations found in healthy subjects, the number of CML target stem cells is estimated for individuals above 20 years of age. The estimation involves three steps. First, CML incidence among adults is fit to an exponentially increasing function of age. Next, assuming a relatively short waiting time distribution between BCR-ABL induction and the appearance of CML, an exponential age function with rate constants fixed to the values found for CML is fitted to the translocation data. Finally, assuming that translocations are equally likely to occur between any two points in the genome, the parameter estimates found in the first two steps are used to estimate the number of target stem cells for CML. The population-averaged estimates of this number are found to be 1.86x10(8) for men and 1.21x10(8) for women; the 95% confidence intervals of these estimates are (1.34x10(8), 2. 50x10(8)) and (0.84x10(8), 1.83x10(8)), respectively.

Entities:  

Mesh:

Year:  1999        PMID: 10525957     DOI: 10.1007/s004110050156

Source DB:  PubMed          Journal:  Radiat Environ Biophys        ISSN: 0301-634X            Impact factor:   1.925


  3 in total

Review 1.  Quantitative modeling of chronic myeloid leukemia: insights from radiobiology.

Authors:  Tomas Radivoyevitch; Lynn Hlatky; Julian Landaw; Rainer K Sachs
Journal:  Blood       Date:  2012-02-21       Impact factor: 22.113

2.  Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation.

Authors:  T Radivoyevitch; R K Sachs; R P Gale; R J Molenaar; D J Brenner; B T Hill; M E Kalaycio; H E Carraway; S Mukherjee; M A Sekeres; J P Maciejewski
Journal:  Leukemia       Date:  2015-09-22       Impact factor: 11.528

3.  Evolutionary Dynamics of Chronic Myeloid Leukemia Progression: the Progression-Inhibitory Effect of Imatinib.

Authors:  Robert C Jackson; Tomas Radivoyevitch
Journal:  AAPS J       Date:  2016-03-23       Impact factor: 4.009

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.